MMP-9 Antibody (4A3) - BSA Free

Western Blot: MMP-9 Antibody (4A3) [NBP2-13173]

MMP-9-Antibody-4A3-Western-Blot-NBP2-13173-img0012.jpg

Immunohistochemistry-Paraffin: MMP-9 Antibody (4A3) [NBP2-13173]

Immunohistochemistry-Paraffin: MMP-9 Antibody (4A3) [NBP2-13173] - Analysis of a FFPE tissue section of human esophageal cancer using MMP9 antibody (clone 4A3) at 1:200. The staining was developed with HRP-labelled secondary antibody and DAB reagent followed by hematoxylin counterstaining. This antibody generated a specific extracellular and cytoplasmic staining primarily in the cancer cells while the signal was pretty weak in the tumor stroma.

Immunohistochemistry-Paraffin: MMP-9 Antibody (4A3) [NBP2-13173]

Immunohistochemistry-Paraffin: MMP-9 Antibody (4A3) [NBP2-13173] - Analysis of a FFPE section of human esophageal cancer using MMP9 antibody (clone 4A3) at 1:200. The staining was developed with HRP-labelled secondary antibody and DAB reagent followed by hematoxylin counterstaining. This antibody clone generated an extracellular and cytoplasmic staining mainly in the cancer cells while the signal was very weak in the stromal cells of the tumor.

Western Blot: MMP-9 Antibody (4A3) [NBP2-13173] -

Western Blot: MMP-9 Antibody (4A3) [NBP2-13173] - 2-DZ analysis & identification of MMP-9 by Western blot. Left panels (A & B): 2-D zymography (2-DZ) of serum samples from healthy control (A) & from an inactive RR-MS patient not subjected to therapy (same patient as in Fig. 2; B). For 2-DZ, aliquots of 35 μl of serum were resuspended in the rehydration solution & subjected to isoelectrofocusing (IEF; 1st dimension) on IPG Dry-Strips of 13 cm in a linear pH gradient of 4–7. After IEF, IPG strips were equilibrated & then applied for the 2nd dimension in a 8.5% (w/v) polyacrylamide gel copolymerized with 0.1% (w/v) gelatin. The isoforms & charge variants of MMP-2 & MMP-9 appear as clear spots of digestion on the dark background of the gel. Right panels (A' & B') represent Western blot analysis of the same sera shown in A & B. Aliquots of 35 μl of serum samples (instead of the usual 20 μl) were subjected to 2D electrophoresis (2-DE) by using 8.5% (w/v) polyacrylamide gels without gelatin. After transfer of the proteins, the nitrocellulose membranes were incubated with an anti MMP-9 (Ab-8) Mouse mAb (IA5) at concentration of 2.66 μg/ml. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/24616914), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: MMP-9 Antibody (4A3) [NBP2-13173] -

Western Blot: MMP-9 Antibody (4A3) [NBP2-13173] - 2-DZ analysis & identification of MMP-9 by Western blot. Left panels (A & B): 2-D zymography (2-DZ) of serum samples from healthy control (A) & from an inactive RR-MS patient not subjected to therapy (same patient as in Fig. 2; B). For 2-DZ, aliquots of 35 μl of serum were resuspended in the rehydration solution & subjected to isoelectrofocusing (IEF; 1st dimension) on IPG Dry-Strips of 13 cm in a linear pH gradient of 4–7. After IEF, IPG strips were equilibrated & then applied for the 2nd dimension in a 8.5% (w/v) polyacrylamide gel copolymerized with 0.1% (w/v) gelatin. The isoforms & charge variants of MMP-2 & MMP-9 appear as clear spots of digestion on the dark background of the gel. Right panels (A' & B') represent Western blot analysis of the same sera shown in A & B. Aliquots of 35 μl of serum samples (instead of the usual 20 μl) were subjected to 2D electrophoresis (2-DE) by using 8.5% (w/v) polyacrylamide gels without gelatin. After transfer of the proteins, the nitrocellulose membranes were incubated with an anti MMP-9 (Ab-8) Mouse mAb (IA5) at concentration of 2.66 μg/ml. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/24616914), licensed under a CC-BY license. Not internally tested by Novus Biologicals.